Venlafaxine XR treatment for older patients with major depressive disorder: decision trees for when to change treatment.
Venlafaxine XR treatment for older patients with major depressive disorder: decision trees for when to change treatment.
复制标题
DOI：
10.1136/ebmental-2022-300479
复制
发表时间：
2022-11
影响因子：
5.2
通讯作者：
中科院分区：
文献类型：
--
作者：
Predictors of antidepressant response in older patients with major depressive disorder (MDD) need to be confirmed before they can guide treatment. To create decision trees for early identification of older patients with MDD who are unlikely to respond to 12 weeks of antidepressant treatment, we analyzed data from 454 older participants treated with venlafaxine XR (150–300mg/d) for up to 12 weeks in the Incomplete Response in Late-Life Depression: Getting to Remission (IRL-Grey) study. We selected the earliest decision point when we could detect participants who had not yet responded (defined as >50% symptom improvement) but would do so after 12 weeks of treatment. Using receiver operating characteristic models, we created two decision trees to minimize either false identification of future responders (false positives) or false identification of future non-responders (false negatives). These decision trees integrated baseline characteristics and treatment response at the early decision point as predictors. We selected week-4 as the optimal early decision point. Both decision trees shared minimal symptom reduction at week-4, longer episode duration, and not having responded to an antidepressant previously as predictors of non-response. Test negative predictive values of the leftmost terminal node of the two trees were 77.4% and 76.6%, respectively. Our decision trees have the potential to guide treatment in older patients with MDD but they require to be validated in other larger samples. Once confirmed, our findings may be used to guide changes in antidepressant treatment in older patients with poor early response.
登录
查看更多内容
影响因子：
6.6
作者：
Olgiati, Paolo;Serretti, Alessandro;Mendlewicz, Julien
通讯作者：
Mendlewicz, Julien
影响因子：
6.7
作者：
Kautzky A;Dold M;Bartova L;Spies M;Kranz GS;Souery D;Montgomery S;Mendlewicz J;Zohar J;Fabbri C;Serretti A;Lanzenberger R;Dikeos D;Rujescu D;Kasper S
通讯作者：
Kasper S
DOI：
10.1016/s0140-6736(15)00308-6
发表时间：
2015-12-12
期刊：
Lancet (London, England)
影响因子：
--
作者：
Lenze EJ;Mulsant BH;Blumberger DM;Karp JF;Newcomer JW;Anderson SJ;Dew MA;Butters MA;Stack JA;Begley AE;Reynolds CF 3rd
通讯作者：
Reynolds CF 3rd
影响因子：
7.2
作者：
Joel, Ian;Begley, Amy E.;Mulsant, Benoit H.;Lenze, Eric J.;Mazumdar, Sati;Dew, Mary Amanda;Blumberger, Daniel;Butters, Meryl;Reynolds, Charles F., III
通讯作者：
Reynolds, Charles F., III
影响因子：
6.7
作者：
DAVIDSON, J;TURNBULL, CD;GRAVES, K
通讯作者：
GRAVES, K